Could a cheap cholesterol drug help fight COVID-19? – Medical News Today

Read Time:4 Minute, 38 Second

All data and statistics are based on publicly available data at the time of publication. Some information may be out of date.
An international effort — involving scientists from Keele University and the University of Birmingham, both in the United Kingdom, and the San Raffaele Scientific Institute in Milan — has found that a drug that people formerly used to control cholesterol levels could be an effective treatment against COVID-19.
The results of the study will appear in the journal Frontiers in Pharmacology.
Researchers first tested several licensed drugs. They were looking for any that disrupted interactions between the viral spike protein — that is, the part of the virus that binds to host cells — and the surface of human cells to see if it would be possible to repurpose the drugs as a COVID-19 treatment.
Co-corresponding study author Dr. Alan Richardson, of Keele University, told Medical News Today: “We tested more than 100 drugs and found that fibric acids had the most potential. Initially, clofibrate looked good, but it has adverse effects, so we then looked at fenofibrate.”
Scientists developed fenofibrate in the 1980s, and doctors used it widely to control people’s cholesterol levels. It was popular until the discovery of statins, which have the added benefit of reducing the risk of heart disease.
Around 30 million people worldwide now take statins. However, some people who cannot tolerate statins still take fenofibrate.
In laboratory experiments, the researchers found that fenofibrate destabilized the spike protein and inhibited binding to the ACE2 membrane protein, through which the virus enters the cells.
Stay informed with live updates on the current COVID-19 outbreak and visit our coronavirus hub for more advice on prevention and treatment.
The drug is effective against the Alpha and Beta variants of SARS-CoV-2, and the team is now investigating its effectiveness against the Delta variant.
“Because the drug affects multiple targets, not just the spike protein, it will be harder for resistance to develop, so new variants should not be able to escape the effect.”
— Dr. Alan Richardson
After experiments with the isolated protein, other researchers in the team repeated the experiments with the live virus and found that fenofibrate was equally effective against the live virus.
Co-corresponding study author Dr. Farhat Khanim, director of research in the School of Biomedical Sciences at the University of Birmingham, tested the drug against the live virus. She was optimistic about its potential.
“We are cautiously very excited. We cannot lose sight of the fact that there are groups of patients at high risk, for whom the vaccine will not work,” she told MNT. “There is still an urgent need to expand our arsenal of drugs to treat SARS-CoV-2 […].”
“The drug seems to work, irrespective of spike mutations,” said Dr. Khanim.
The researchers then looked at how much virus infected cells released after treatment with fenofibrate in vitro. They found that there was a 60% reduction in viral release compared with untreated cells. Other drugs, such as statins, did not have a similar effect.
“Fenofibrate seems to do more than statins.”
— Dr. Farhat Khanim
The viral reproduction and spread among cells are what causes the symptoms as the body tries to control the virus. A drug that reduces that viral release should prevent severe disease and hospitalization and reduce the risk of those with SARS-CoV-2 passing it on to others.
Because people can take the drug by mouth and because the molecule is very cheap, if scientists replicate the recent finding in clinical trials, fenofibrate could prove invaluable for low and middle income countries that have not been able to get ahead with vaccination.
Dr. Richardson added: “Fenofibrate is widely available. We estimate that the cost of a course of treatment would be about £10–20 [$14–28].”
Dr. Peter English, a retired consultant in communicable disease control and immediate past chair of the BMA public health medicine committee, says that “[i]f this in vitro finding translates into a useful clinical effect, it may add another drug to our armory.” Dr. English was not involved with the recent study.
He adds that “[a]t present, however, all of this is fairly speculative because as yet this drug has not yet moved from laboratory-based studies.”
The study authors advise caution around their findings, as all results are from laboratory trials. They are now keen to start clinical trials to assess fenofibrate as a potential therapeutic agent for COVID-19.
“I would like to see clinical trials in high risk populations in the community with symptoms, starting treatment early to see if it prevents hospitalization,” Dr. Khanim told MNT.
For live updates on the latest developments regarding the novel coronavirus and COVID-19, click 
No current medicine can prevent or cure COVID-19. However, scientists are investigating options, and some drugs already have approval. Find out more…
In this Special Feature, we look at monoclonal antibody therapy for COVID-19. We cover what it is, the evidence for it, and the research currently…
COVID-19 is a highly contagious infectious disease resulting from a recently identified coronavirus. Learn to curb its spread and more here.
COVID-19 shares some similarities with other respiratory conditions, such as the common cold and influenza, although there are also crucial…
The common cold and COVID-19 can result in similar symptoms. However, there are some key differences in the symptoms and potential severity.
OUR BRANDS

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %

Average Rating

5 Star
0%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous post Staying in the Game: Why You Need a Primary Care Sports Medicine Doctor – NYU Langone Health
Next post Robotic & Minimally Invasive Heart Surgery I Ohio State Medical Center – Wexner Medical Center – The Ohio State University
Close